New CEO for HALIX
HALIX B.V., a CDMO specializing in the development and manufacturing of complex therapeutic antibodies (proteins) and viral products, appointed Dr. Lutz Hilbrich as CEO in Sept 2024.
With over 20 years in the biotechnology and pharmaceutical sectors, Dr. Hilbrich brings extensive experience in strategic leadership, operational excellence, and innovation in biopharmaceutical development and manufacturing. He succeeds Alex Huybens, who has built and led HALIX’s activities in recent years.
Dr. Hilbrich worked across multiple regions, including the US, China, Europe, and Africa, in both big pharma and mid-sized companies. HALIX partnered with AstraZeneca for the development and manufacturing (clinical and commercial scale) of its COVID-19 vaccine, underscoring its capability to support global healthcare initiatives.